What's breaking now, across thousands of outlets.
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
We haven't written up this one. The Economic Times - Top News has the full story — the link below goes straight to it.
A single gene-editing treatment could someday protect against heart disease, high cholesterol, and other common conditions for decades, potentially replacing lifelong medications.
KUALA LUMPUR, Nov 4 (Bernama) -- AGC Biologics has expanded its existing long-term manufacturing agreement with a global pharmaceutical company to include its Copenhagen facility, lifting the deal’s…
Scientists have developed a promising new cancer-fighting strategy that uses carbon monoxide naturally produced by tumor cells to manufacture powerful drugs inside the cancer cells themselves.
The proposed amendment to Rule 43A of the Drugs Rules, 1945, is aimed at easing import operations, reducing inland transportation distances and improving the movement of healthcare products across the…
On One Health, gender disparities in healthcare, emerging research, infectious diseases and more
